The germline p53 activation syndrome: A new patient further refines the clinical phenotype.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
07 2022
Historique:
revised: 01 03 2022
received: 22 12 2021
accepted: 18 03 2022
pubmed: 2 4 2022
medline: 15 6 2022
entrez: 1 4 2022
Statut: ppublish

Résumé

The tumor suppressor p53 has well known roles in cancer development and germline cancer predisposition disorders, but increasing evidence supports the role of activation of this transcription factor in the pathogenesis of inherited bone marrow failure and chromosomal instability disorders. Here we report a patient with red cell aplasia, which was steroid responsive, as well as intellectual disability, seizures, microcephaly, short stature, cellular radiosensitivity, and normal telomere lengths, who had a germline heterozygous C-terminal frameshift variant in TP53 similar to others that activate the transcription factor. This is the third reported individual with a germline p53 activation syndrome, with several unique features that refine the clinical disease associated with these variants.

Identifiants

pubmed: 35362179
doi: 10.1002/ajmg.a.62749
doi:

Substances chimiques

Transcription Factors 0
Tumor Suppressor Protein p53 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

2204-2208

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Baerlocher, G. M., Vulto, I., de Jong, G., & Lansdorp, P. M. (2006). Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nature Protocols, 1(5), 2365-2376. https://doi.org/10.1038/nprot.2006.263
Bowen, M. E., & Attardi, L. D. (2019). The role of p53 in developmental syndromes. Journal of Molecular Cell Biology, 11(3), 200-211. https://doi.org/10.1093/jmcb/mjy087
Chrzanowska, K. H., Gregorek, H., Dembowska-Bagińska, B., Kalina, M. A., & Digweed, M. (2012). Nijmegen breakage syndrome (NBS). Orphanet Journal of Rare Diseases, 7, 13. https://doi.org/10.1186/1750-1172-7-13
Dyle, M. C., Kolakada, D., Cortazar, M. A., & Jagannathan, S. (2020). How to get away with nonsense: Mechanisms and consequences of escape from nonsense-mediated RNA decay. Wiley Interdisciplinary Reviews RNA, 11(1), e1560. https://doi.org/10.1002/wrna.1560
Fedorova, D., Ovsyannikova, G., Kurnikova, M., Pavlova, A., Konyukhova, T., Pshonkin, A., & Smetanina, N. (2022). De novo TP53 germline activating mutations in two patients with the phenotype mimicking Diamond-Blackfan anemia. Pediatric Blood & Cancer, 69(4), e29558. https://doi.org/10.1002/pbc.29558
Gatti, R. A. (2001). The inherited basis of human radiosensitivity. Acta Oncologica (Stockholm, Sweden), 40(6), 702-711. https://doi.org/10.1080/02841860152619115
Hamard, P. J., Barthelery, N., Hogstad, B., Mungamuri, S. K., Tonnessen, C. A., Carvajal, L. A., Senturk, E., Gillespie, V., Aaronson, S. A., Merad, M., & Manfredi, J. J. (2013). The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. Genes & Development, 27(17), 1868-1885. https://doi.org/10.1101/gad.224386.113
Kumar, R. D., Burns, B. A., Vandeventer, P. J., Luna, P. N., & Shaw, C. A. (2021). Selection for or against escape from nonsense mediated decay is a novel signature for the detection of cancer genes. Cancer Genetics, 258-259, 80-84. https://doi.org/10.1016/j.cancergen.2021.09.003
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. J., Gabizon, R., Mattia, M., Zupnick, A., Brown, L. M., Friedler, A., & Prives, C. (2010). The C terminus of p53 binds the N-terminal domain of MDM2. Nature Structural & Molecular Biology, 17(8), 982-989. https://doi.org/10.1038/nsmb.1872
Simeonova, I., Jaber, S., Draskovic, I., Bardot, B., Fang, M., Bouarich-Bourimi, R., Lejour, V., Charbonnier, L., Soudais, C., Bourdon, J. C., Huerre, M., Londono-Vallejo, A., & Toledo, F. (2013). Mutant mice lacking the p53 C-terminal domain model telomere syndromes. Cell Reports, 3(6), 2046-2058. https://doi.org/10.1016/j.celrep.2013.05.028
Sun, X., Becker-Catania, S. G., Chun, H. H., Hwang, M. J., Huo, Y., Wang, Z., Mitui, M., Sanal, O., Chessa, L., Crandall, B., & Gatti, R. A. (2002). Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. Journal of Pediatrics, 140(6), 724-731. https://doi.org/10.1067/mpd.2002.123879
Toki, T., Yoshida, K., Wang, R., Nakamura, S., Maekawa, T., Goi, K., Katoh, M. C., Mizuno, S., Sugiyama, F., Kanezaki, R., Uechi, T., Nakajima, Y., Sato, Y., Okuno, Y., Sato-Otsubo, A., Shiozawa, Y., Kataoka, K., Shiraishi, Y., Sanada, M., … Ito, E. (2018). De novo mutations activating germline TP53 in an inherited bone-marrow-failure syndrome. American Journal of Human Genetics, 103(3), 440-447.
Toufektchan, E., Lejour, V., Durand, R., Giri, N., Draskovic, I., Bardot, B., Laplante, P., Jaber, S., Alter, B. P., Londono-Vallejo, J.-A., Savage, S. A., & Toledo, F. (2020). Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Science Advances, 6(15), eaay3511. https://doi.org/10.1126/sciadv.aay3511
Vlachos, A., Atsidaftos, E., Lababidi, M. L., Muir, E., Rogers, Z. R., Alhushki, W., Bernstein, J., Glader, B., Gruner, B., Hartung, H., Knoll, C., Loew, T., Nalepa, G., Narla, A., Panigrahi, A. R., Sieff, C. A., Walkovich, K., Farrar, J. E., & Lipton, J. M. (2020). L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan anemia registry. Pediatric Blood & Cancer, 67(12), e28748. https://doi.org/10.1002/pbc.28748
Vlachos, A., & Muir, E. (2010). How I treat Diamond-Blackfan anemia. Blood, 116(19), 3715-3723. https://doi.org/10.1182/blood-2010-02-251090

Auteurs

Runjun D Kumar (RD)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

Mustafa Tosur (M)

Department of Pediatrics, Division of Diabetes and Endocrinology, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Hospital, Houston, Texas, USA.

Seema R Lalani (SR)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Hospital, Houston, Texas, USA.

Donald H Mahoney (DH)

Texas Children's Hospital, Houston, Texas, USA.
Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.

Alison A Bertuch (AA)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Texas Children's Hospital, Houston, Texas, USA.
Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH